GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Hengrui Pharmaceuticals Co Ltd (SHSE:600276) » Definitions » Change In Payables And Accrued Expense

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Change In Payables And Accrued Expense : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Jiangsu Hengrui Pharmaceuticals Co Change In Payables And Accrued Expense?

Jiangsu Hengrui Pharmaceuticals Co's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Jiangsu Hengrui Pharmaceuticals Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

Jiangsu Hengrui Pharmaceuticals Co's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was ¥0 Mil. It means Jiangsu Hengrui Pharmaceuticals Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .


Jiangsu Hengrui Pharmaceuticals Co Change In Payables And Accrued Expense Historical Data

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Hengrui Pharmaceuticals Co Change In Payables And Accrued Expense Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Jiangsu Hengrui Pharmaceuticals Co Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Hengrui Pharmaceuticals Co Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Jiangsu Hengrui Pharmaceuticals Co's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Business Description

Traded in Other Exchanges
N/A
Address
No. 38, Huanghe Road, Economic, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222047
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Headlines

No Headlines